Received Oct 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
1st dose Shingrix in Sept 2019 and then a second dose in July 2025; This non-serious case was reported by a physician via call center representative and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received on in September 2019). In JUL-2025, the patient received the 2nd dose of Shingrix. In JUL-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: 1st dose Shingrix in Sept 2019 and then a second dose in July 2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 15-OCT-2025 A healthcare provider inquired about a patient who had received a Shingrix dose in September 2019 and a second dose in July 2025, asking whether a third dose was necessary. They noted that CDC guidance appeared to indicate no need for a repeat, but some colleagues had recommended a third dose for their patients. The agent asked if those colleagues might have administered third doses due to delayed second doses. The provider acknowledged that possibility, explaining the second dose had been given well beyond the recommended 2-to-6-month interval. The patient did not consent to follow-up. The batch number was not provided upon follow up with the reporter.